Anticancer agent 324
Anticancer agent 324 is a Survivin inhibitor. Anticancer agent 324 competitively binds to Survivin’s linker region and triggers proteasomal IAP degradation. Anticancer agent 324 blocks Borealin binding and chromosomal passenger complex formation, and inhibits Survivin-CRM1 nuclear-cytoplasmic transport. Anticancer agent 324 activates extrinsic (caspase-8) and intrinsic (caspase-9) apoptotic pathways, activates executioner caspases-3 and caspases-7, and arrests cell cycle. Anticancer agent 324 can be used for the research of breast cancer.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Formule: C85H130N28O21S
- Masse moléculaire:1912.18
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Voir tous les produits spécifiques à Isoform Caspase
More
Activité biologique
|
Caspase-3 |
Caspase-7 |
Caspase-8 |
Caspase-9 |
Anticancer agent 324 (Compound P3) binds with higher affinity to the linker region of Survivin than cIAP1, NAIP, and XIAP, enabling it to competitively disrupt Survivin's protective interactions with these IAP family members[1].
Anticancer agent 324 (5-50 μM; 24-48 h) reduces MCF-7 human breast cancer cell viability in a time-dependent manner[1].
Anticancer agent 324 (15-45 μM; 24-48 h) induces caspase-3 and -7 activity in MCF-7 human breast cancer cells in vitro in a time-dependent manner[1].
Anticancer agent 324 (25 μM; 48 h) significantly activates both caspase-8 (extrinsic pathway) and caspase-9 (intrinsic pathway) in MCF-7 human breast cancer cells[1].
Anticancer agent 324 (25 μM; 48 h) significantly increases apoptosis and mitotic catastrophe in MCF-7 human breast cancer cells after 48 h incubation[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:MCF-7 human breast cancer cells
-
Concentration:5 μM; 10 μM; 15 μM; 20 μM; 25 μM; 30 μM; 35 μM; 40 μM; 45 μM; 50 μM
-
Incubation Time:24 h; 48 h
-
Result:Reduced MCF-7 cell viability in a time-dependent manner.
Reached an IC50 of 40 μM at 24 h and 25 μM at 48 h.
Showed significant reductions in viability at all tested concentrations relative to control at 48 h, with effect sizes (Cohen's d) ranging from 6.20 to 19.52.
-
Cell Line:MCF-7 human breast cancer cells
-
Concentration:15 μM; 25 μM; 35 μM; 45 μM
-
Incubation Time:24 h; 48 h
-
Result:Increased total apoptosis to 82.78% at 25 μM, with significant increases in early apoptosis (18.7%, p = 0.0044, Cohen's d = -4.73) and late apoptosis (64.1%, p = 2.86e-05, Cohen's d = -17.4), and minimal non-significant necrosis (1.36%, p = 0.0868).
Increased total apoptosis to 23.23% at 45 μM, with significant increases only in late apoptosis (19.2%, p = 0.001, Cohen's d = 5.53) and necrosis (13.1%, p = 0.0043, Cohen's d = 5.86), while early apoptosis did not change significantly (p = 0.462).
-
Cell Line:MCF-7 human breast cancer cells
-
Concentration:25 μM
-
Incubation Time:48 h
-
Result:Significantly increased the proportion of non-viable cells (red fluorescence from PI) relative to control (p = 0.00011), confirming induction of apoptosis and mitotic catastrophe.
Chemical Information
-
Masse moléculaire 1912.18
-
Formule C85H130N28O21S
-
Sequence
Arg-Arg-Arg-Leu-Arg-Glu-Met-Asn-Trp-Val-Asp-Tyr-Phe-Ala
-
Sequence Shortening
RRRLREMNWVDYFA
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Anticancer agent 324 Related Classifications
HY-P11828 Related Classifications
Powered by Bioz